Blood Biomarkers of Uveal Melanoma: Current Perspectives

References

• Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol. 1978;62(6):420–425. doi:10.1136/bjo.62.6.420
   PubMed Web of Science ®Google Scholar
• Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007;114(10):1925–1931. doi:10.1016/j.ophtha.2007.06.012
   PubMed Web of Science ®Google Scholar
• Shields CL, Ganguly A, Materin MA, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. Trans Am Ophthalmol Soc. 2007;105:43–52; discussion 52–43.
   Google Scholar
• Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res. 2010;16(24):6083–6092. doi:10.1158/1078-0432.CCR-10-2076
   PubMed Web of Science ®Google Scholar
• Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25(3):234–239. doi:10.1097/ICU.0000000000000051
   PubMed Web of Science ®Google Scholar
• Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463–466. doi:10.1097/COH.0b013e32833ed177
   PubMed Web of Science ®Google Scholar
• Gombos DS, Van Quill KR, Uusitalo M, O’Brien JM. Geographic disparities in diagnostic screening for metastatic uveal melanoma. Ophthalmology. 2004;111(12):2254–2258. doi:10.1016/j.ophtha.2004.06.022
   Web of Science ®Google Scholar
• Donoso LA, Berd D, Augsburger JJ, Mastrangelo MJ, Shields JA. Metastatic uveal melanoma. Pretherapy serum liver enzyme and liver scan abnormalities. Arch Ophthalmol. 1985;103(6):796–798. doi:10.1001/archopht.1985.01050060056024
   Google Scholar
• Eskelin S, Pyrhonen S, Summanen P, Prause JU, Kivela T. Screening for metastatic malignant melanoma of the uvea revisited. Cancer. 1999;85(5):1151–1159. doi:10.1002/(SICI)1097-0142(19990301)85:5<1151::AID-CNCR20>3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Mafee MF. Uveal melanoma, choroidal hemangioma, and simulating lesions. Role of MR imaging. Radiol Clin North Am. 1998;36(6):1083–1099, x. doi:10.1016/S0033-8389(05)70233-5
   Web of Science ®Google Scholar
• Damato B. Developments in the management of uveal melanoma. Clin Experiment Ophthalmol. 2004;32(6):639–647. doi:10.1111/ceo.2004.32.issue-6
   PubMed Web of Science ®Google Scholar
• Diener-West M, Reynolds SM, Agugliaro DJ, et al. Screening for metastasis from choroidal melanoma: the collaborative ocular melanoma study group report 23. J Clin Oncol. 2004;22(12):2438–2444. doi:10.1200/JCO.2004.08.194
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Burgess MA, Gottlieb JA. Metastatic patterns of choroidal melanoma. Cancer. 1974;34(4):1001–1004. doi:10.1002/(ISSN)1097-0142
   Web of Science ®Google Scholar
• Hicks C, Foss AJ, Hungerford JL. Predictive power of screening tests for metastasis in uveal melanoma. Eye. 1998;12(Pt 6):945–948. doi:10.1038/eye.1998.245
   Web of Science ®Google Scholar
• Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology. 2000;107(8):1443–1449. doi:10.1016/S0161-6420(00)00182-2
   PubMed Web of Science ®Google Scholar
• Kaiserman I, Amer R, Pe’er J. Liver function tests in metastatic uveal melanoma. Am J Ophthalmol. 2004;137(2):236–243. doi:10.1016/j.ajo.2003.08.045
   Web of Science ®Google Scholar
• Wollina U, Karte K, Hipler UC, Knoll B, Kirsch K, Herold C. Serum protein s100beta in patients with malignant melanoma detected by an immunoluminometric assay. J Cancer Res Clin Oncol. 2000;126(2):107–110. doi:10.1007/s004320050018
   Web of Science ®Google Scholar
• Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995;31A(11):1898–1902. doi:10.1016/0959-8049(95)00087-Y
   Web of Science ®Google Scholar
• Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun. 1965;19(6):739–744. doi:10.1016/0006-291X(65)90320-7
   PubMed Web of Science ®Google Scholar
• Shi S, Wang G, Zhang K, et al. Expression of S100beta protein in patients with vascular dementia after basal ganglia hemorrhage and its clinical significance. Exp Ther Med. 2017;13(5):1917–1921. doi:10.3892/etm.2017.4207
   Web of Science ®Google Scholar
• Nomura-Komoike K, Saitoh F, Komoike Y, Fujieda H. DNA damage response in proliferating muller glia in the mammalian retina. Invest Ophthalmol Vis Sci. 2016;57(3):1169–1182. doi:10.1167/iovs.15-18101
   Web of Science ®Google Scholar
• Cochran AJ, Holland GN, Saxton RE, et al. Detection and quantification of S-100 protein in ocular tissues and fluids from patients with intraocular melanoma. Br J Ophthalmol. 1988;72(11):874–879. doi:10.1136/bjo.72.11.874
   Web of Science ®Google Scholar
• Cochran AJ, Holland GN, Wen DR, et al. Detection of cytoplasmic S-100 protein in primary and metastatic intraocular melanomas. Invest Ophthalmol Vis Sci. 1983;24(8):1153–1155.
   Web of Science ®Google Scholar
• Missotten GS, Tang NE, Korse CM, et al. Prognostic value of S-100-beta serum concentration in patients with uveal melanoma. Arch Ophthalmol. 2003;121(8):1117–1119. doi:10.1001/archopht.121.8.1117
   PubMedGoogle Scholar
• Missotten GS, Korse CM, van Dehn C, et al. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Tumour Biol. 2007;28(2):63–69. doi:10.1159/000099151
   Google Scholar
• Blesch A, Bosserhoff AK, Apfel R, et al. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res. 1994;54(21):5695–5701.
   PubMed Web of Science ®Google Scholar
• Bosserhoff AK, Moser M, Hein R, Landthaler M, Buettner R. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers. J Pathol. 1999;187(4):446–454. doi:10.1002/(SICI)1096-9896(199903)187:4<446::AID-PATH267>3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Bosserhoff AK, Buettner R. Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Histol Histopathol. 2002;17(1):289–300. doi:10.14670/HH-17.289
   Web of Science ®Google Scholar
• Bosserhoff AK, Lederer M, Kaufmann M, et al. MIA, a novel serum marker for progression of malignant melanoma. Anticancer Res. 1999;19(4A):2691–2693.
   Web of Science ®Google Scholar
• Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res. 2002;12(6):593–599. doi:10.1097/00008390-200212000-00009
   Web of Science ®Google Scholar
• Reiniger IW, Schaller UC, Haritoglou C, et al. “Melanoma inhibitory activity” (MIA): a promising serological tumour marker in metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2005;243(11):1161–1166. doi:10.1007/s00417-005-1171-4
   Web of Science ®Google Scholar
• Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol. 2002;161(6):2035–2046. doi:10.1016/S0002-9440(10)64482-3
   PubMed Web of Science ®Google Scholar
• Zhao H, Chen Q, Alam A, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis. 2018;9(3):356. doi:10.1038/s41419-018-0391-6
   PubMed Web of Science ®Google Scholar
• Zhou Y, Dai DL, Martinka M, et al. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005;124(5):1044–1052. doi:10.1111/j.0022-202X.2005.23680.x
   Web of Science ®Google Scholar
• Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004;90(10):1877–1881. doi:10.1038/sj.bjc.6601839
   Web of Science ®Google Scholar
• Denhardt D. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005;124(5):xvi–xviii. doi:10.1111/j.0022-202X.2005.23708.x
   Web of Science ®Google Scholar
• Kadkol SS, Lin AY, Barak V, et al. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci. 2006;47(3):802–806. doi:10.1167/iovs.05-0422
   Web of Science ®Google Scholar
• Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe’er J. Serum markers to detect metastatic uveal melanoma. Anticancer Res. 2007;27(4A):1897–1900.
   Web of Science ®Google Scholar
• Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R, Schaller UC. Osteopontin and ‘melanoma inhibitory activity’: comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica. 2009;223(4):239–243. doi:10.1159/000206139
   Web of Science ®Google Scholar
• Suesskind D, Schatz A, Schnichels S, et al. GDF-15: a novel serum marker for metastases in uveal melanoma patients. Graefes Arch Clin Exp Ophthalmol. 2012;250(6):887–895. doi:10.1007/s00417-011-1786-6
   PubMed Web of Science ®Google Scholar
• Barak V, Kaiserman I, Frenkel S, Hendler K, Kalickman I, Pe’er J. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1). Anticancer Res. 2011;31(1):345–349.
   Web of Science ®Google Scholar
• Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997;94(21):11514–11519. doi:10.1073/pnas.94.21.11514
   PubMed Web of Science ®Google Scholar
• Boyle GM, Pedley J, Martyn AC, et al. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol. 2009;129(2):383–391. doi:10.1038/jid.2008.270
   PubMed Web of Science ®Google Scholar
• Amaro A, Gangemi R, Piaggio F, et al. The biology of uveal melanoma. Cancer Metastasis Rev. 2017;36(1):109–140.
   PubMed Web of Science ®Google Scholar
• Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev. 2007;28(3):297–321.
   PubMed Web of Science ®Google Scholar
• Kivela T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin. 2006;46(1):133–149. doi:10.1097/01.iio.0000195861.71558.13
   Google Scholar
• Hendrix MJ, Seftor EA, Seftor RE, et al. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Pathol. 1998;152(4):855–863.
   Web of Science ®Google Scholar
• Seftor EA, Meltzer PS, Kirschmann DA, et al. Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis. 2002;19(3):233–246. doi:10.1023/A:1015591624171
   PubMed Web of Science ®Google Scholar
• Frenkel S, Zloto O, Pe’er J, Barak V. Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans. Invest Ophthalmol Vis Sci. 2013;54(1):490–493. doi:10.1167/iovs.12-10228
   Web of Science ®Google Scholar
• Bondy CA, Werner H, Roberts CT Jr., LeRoith D. Cellular pattern of insulin-like growth factor-I (IGF-I) and type I IGF receptor gene expression in early organogenesis: comparison with IGF-II gene expression. Mol Endocrinol. 1990;4(9):1386–1398. doi:10.1210/mend-4-9-1386
   Google Scholar
• Pollak MN. Insulin-like growth factors and neoplasia. Novartis Found Symp. 2004;262:84–98;discussion 98–107, 265–108.
   Google Scholar
• Al-Jamal RT, Kivela T. Prognostic associations of insulin-like growth factor-1 receptor in primary uveal melanoma. Can J Ophthalmol. 2011;46(6):471–476. doi:10.1016/j.jcjo.2011.09.013
   Web of Science ®Google Scholar
• Boyd SR, Tan D, Bunce C, et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol. 2002;86(4):448–452. doi:10.1136/bjo.86.4.448
   Web of Science ®Google Scholar
• Missotten GS, Notting IC, Schlingemann RO, et al. Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol. 2006;124(10):1428–1434. doi:10.1001/archopht.124.10.1428
   PubMedGoogle Scholar
• El Filali M, GS M, Maat W, et al. Regulation of VEGF-A in uveal melanoma. Invest Ophthalmol Vis Sci. 2010;51(5):2329–2337. doi:10.1167/iovs.09-4739
   PubMed Web of Science ®Google Scholar
• Barak V, Pe’er J, Kalickman I, Frenkel S. VEGF as a biomarker for metastatic uveal melanoma in humans. Curr Eye Res. 2011;36(4):386–390. doi:10.3109/02713683.2010.534573
   PubMed Web of Science ®Google Scholar
• Ijland SA, Jager MJ, Heijdra BM, Westphal JR, Peek R. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res. 1999;9(5):445–450. doi:10.1097/00008390-199910000-00003
   Web of Science ®Google Scholar
• Anastassiou G, Schilling H, Stang A, Djakovic S, Heiligenhaus A, Bornfeld N. Expression of the cell adhesion molecules ICAM-1, VCAM-1 and NCAM in uveal melanoma: a clinicopathological study. Oncology. 2000;58(1):83–88. doi:10.1159/000012083
   Web of Science ®Google Scholar
• Lai K, Conway RM, Crouch R, Jager MJ, Madigan MC. Expression and distribution of MMPs and TIMPs in human uveal melanoma. Exp Eye Res. 2008;86(6):936–941. doi:10.1016/j.exer.2008.03.010
   Web of Science ®Google Scholar
• Kruckel A, Moreira A, Frohlich W, Schuler G, Heinzerling L. Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma. BMC Cancer. 2019;19(1):207. doi:10.1186/s12885-019-5384-z
   Web of Science ®Google Scholar
• Michelson JB, Felberg NT, Shields JA. Carcinoembryonic antigen. Its role in the evaluation of intraocular malignant tumors. Arch Ophthalmol. 1976;94(3):414–416. doi:10.1001/archopht.1976.03910030200005
   PubMedGoogle Scholar
• Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270(8):943–947. doi:10.1001/jama.1993.03510080047030
   PubMed Web of Science ®Google Scholar
• Kudo Y, Siriwardena BS, Hatano H, Ogawa I, Takata T. Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol. 2007;22(10):1167–1174. doi:10.14670/HH-22.1167
   PubMed Web of Science ®Google Scholar
• Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair. 2012;5(1):7. doi:10.1186/1755-1536-5-7
   PubMedGoogle Scholar
• Pyle-Chenault RA, Stolk JA, Molesh DA, et al. VSGP/F-spondin: a new ovarian cancer marker. Tumour Biol. 2005;26(5):245–257. doi:10.1159/000087379
   Google Scholar
• Song J, Merbs SL, Sokoll LJ, Chan DW, Zhang Z. A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma. Clin Proteomics. 2019;16:10. doi:10.1186/s12014-019-9230-8
   Web of Science ®Google Scholar
• Pardo M, Garcia A, Thomas B, et al. Proteome analysis of a human uveal melanoma primary cell culture by 2-DE and MS. Proteomics. 2005;5(18):4980–4993. doi:10.1002/pmic.200500030
   Web of Science ®Google Scholar
• Wu GJ, Wu MW, Wang SW, et al. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene. 2001;279(1):17–31. doi:10.1016/S0378-1119(01)00736-3
   Web of Science ®Google Scholar
• Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol. 2001;21(2):575–594. doi:10.1128/MCB.21.2.575-594.2001
   PubMed Web of Science ®Google Scholar
• Pardo M, Garcia A, Antrobus R, Blanco MJ, Dwek RA, Zitzmann N. Biomarker discovery from uveal melanoma secretomes: identification of gp100 and cathepsin D in patient serum. J Proteome Res. 2007;6(7):2802–2811. doi:10.1021/pr070021t
   Web of Science ®Google Scholar
• Pardo M, Garcia A, Thomas B, et al. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker. Int J Cancer. 2006;119(5):1014–1022. doi:10.1002/ijc.21942
   Web of Science ®Google Scholar
• Zuidervaart W, Hensbergen PJ, Wong MC, et al. Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression. Invest Ophthalmol Vis Sci. 2006;47(3):786–793. doi:10.1167/iovs.05-0314
   Web of Science ®Google Scholar
• Wang F, Bing Z, Zhang Y, et al. Quantitative proteomic analysis for radiation-induced cell cycle suspension in 92-1 melanoma cell line. J Radiat Res. 2013;54(4):649–662. doi:10.1093/jrr/rrt010
   Web of Science ®Google Scholar
• Yan LB, Shi K, Bing ZT, Sun YL, Shen Y. Proteomic analysis of energy metabolism and signal transduction in irradiated melanoma cells. Int J Ophthalmol. 2013;6(3):286–294. doi:10.3980/j.issn.2222-3959.2013.03.06
   Web of Science ®Google Scholar
• Angi M, Kalirai H, Prendergast S, et al. In-depth proteomic profiling of the uveal melanoma secretome. Oncotarget. 2016;7(31):49623–49635. doi:10.18632/oncotarget.v7i31
   Google Scholar
• Surman M, Hoja-Lukowicz D, Szwed S, et al. An insight into the proteome of uveal melanoma-derived ectosomes reveals the presence of potentially useful biomarkers. Int J Mol Sci. 2019;20:15. doi:10.3390/ijms20153789
   Web of Science ®Google Scholar
• Nagakubo D, Taira T, Kitaura H, et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun. 1997;231(2):509–513. doi:10.1006/bbrc.1997.6132
   PubMed Web of Science ®Google Scholar
• Wilson MA. The role of cysteine oxidation in DJ-1 function and dysfunction. Antioxid Redox Signal. 2011;15(1):111–122. doi:10.1089/ars.2010.3481
   PubMed Web of Science ®Google Scholar
• Vasseur S, Afzal S, Tardivel-Lacombe J, Park DS, Iovanna JL, Mak TW. DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses. Proc Natl Acad Sci U S A. 2009;106(4):1111–1116. doi:10.1073/pnas.0812745106
   PubMed Web of Science ®Google Scholar
• Fan J, Ren H, Jia N, et al. DJ-1 decreases bax expression through repressing p53 transcriptional activity. J Biol Chem. 2008;283(7):4022–4030. doi:10.1074/jbc.M707176200
   PubMed Web of Science ®Google Scholar
• Bande MF, Santiago M, Blanco MJ, et al. Serum DJ-1/PARK 7 is a potential biomarker of choroidal nevi transformation. Invest Ophthalmol Vis Sci. 2012;53(1):62–67. doi:10.1167/iovs.11-7948
   Web of Science ®Google Scholar
• Pineiro-Ces A, Rodriguez Alvarez MJ, Santiago M, et al. Detecting ultrasonographic hollowness in small choroidal melanocytic tumors using 10 MHz and 20 MHz ultrasonography: a comparative study. Graefes Arch Clin Exp Ophthalmol. 2014;252(12):2005–2011. doi:10.1007/s00417-014-2758-4
   Web of Science ®Google Scholar
• Bande MF, Santiago M, Muinelo-Romay L, et al. Detection of circulating melanoma cells in choroidal melanocytic lesions. BMC Res Notes. 2015;8:452. doi:10.1186/s13104-015-1420-5
   Google Scholar
• Chen LL, Tian JJ, Su L, et al. DJ-1: a promising marker in metastatic uveal melanoma. J Cancer Res Clin Oncol. 2015;141(2):315–321. doi:10.1007/s00432-014-1804-2
   PubMed Web of Science ®Google Scholar
• Berson JF, Harper DC, Tenza D, Raposo G, Marks MS. Pmel17 initiates premelanosome morphogenesis within multivesicular bodies. Mol Biol Cell. 2001;12(11):3451–3464. doi:10.1091/mbc.12.11.3451
   PubMed Web of Science ®Google Scholar
• Hoashi T, Tamaki K, Hearing VJ. The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding. FASEB J. 2010;24(3):916–930. doi:10.1096/fj.09-140921
   Web of Science ®Google Scholar
• Bande MF, Santiago M, Mera P, et al. ME20-S as a potential biomarker for the evaluation of uveal melanoma. Invest Ophthalmol Vis Sci. 2015;56(12):7007–7011. doi:10.1167/iovs.15-17183
   Web of Science ®Google Scholar
• Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146.
   Google Scholar
• Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 1991;338(8777):1227–1229. doi:10.1016/0140-6736(91)92100-G
   PubMed Web of Science ®Google Scholar
• Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN Jr. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A Prospective Longitudinal Study. Eye. 2007;21(6):752–759.
   Web of Science ®Google Scholar
• Horodenski J. [Studies on the presence of free cells of malignant melanoma of the uvea in peripheral blood]. Klin Oczna. 1969;39(3):407–412.
   Google Scholar
• Fernandes BF, Belfort RN, Di Cesare S, Burnier MN Jr. Circulating uveal melanoma cells: should we test for them?. Can J Ophthalmol. 2008;43(2):155–158. doi:10.3129/i08-011
   Web of Science ®Google Scholar
• Tobal K, Sherman LS, Foss AJ, Lightman SL. Detection of melanocytes from uveal melanoma in peripheral blood using the polymerase chain reaction. Invest Ophthalmol Vis Sci. 1993;34(9):2622–2625.
   Web of Science ®Google Scholar
• Foss AJ, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer. 1995;72(1):155–159. doi:10.1038/bjc.1995.293
   Web of Science ®Google Scholar
• Boldin I, Langmann G, Richtig E, et al. Five-year results of prognostic value of tyrosinase in peripheral blood of uveal melanoma patients. Melanoma Res. 2005;15(6):503–507. doi:10.1097/00008390-200512000-00004
   Web of Science ®Google Scholar
• Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res. 2006;12(15):4605–4613. doi:10.1158/1078-0432.CCR-06-0823
   Web of Science ®Google Scholar
• Ulmer A, Beutel J, Susskind D, et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res. 2008;14(14):4469–4474. doi:10.1158/1078-0432.CCR-08-0012
   PubMed Web of Science ®Google Scholar
• Suesskind D, Ulmer A, Schiebel U, et al. Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: a pilot study. Acta Ophthalmol (Copenh). 2011;89(1):17–24. doi:10.1111/j.1755-3768.2009.01617.x
   Web of Science ®Google Scholar
• Mazzini C, Pinzani P, Salvianti F, et al. Circulating tumor cells detection and counting in uveal melanomas by a filtration-based method. Cancers. 2014;6(1):323–332. doi:10.3390/cancers6010323
   Web of Science ®Google Scholar
• Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer. 2014;134(5):1207–1213. doi:10.1002/ijc.28436
   PubMed Web of Science ®Google Scholar
• Terai M, Mu Z, Eschelman DJ, et al. Arterial blood, rather than venous blood, is a better source for circulating melanoma cells. EBioMedicine. 2015;2(11):1821–1826. doi:10.1016/j.ebiom.2015.09.019
   Web of Science ®Google Scholar
• Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004. doi:10.1038/sigtrans.2015.4
   PubMed Web of Science ®Google Scholar
• Worley LA, Long MD, Onken MD, Harbour JW. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res. 2008;18(3):184–190. doi:10.1097/CMR.0b013e3282feeac6
   PubMed Web of Science ®Google Scholar
• Achberger S, Aldrich W, Tubbs R, Crabb JW, Singh AD, Triozzi PL. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol Immunol. 2014;58(2):182–186. doi:10.1016/j.molimm.2013.11.018
   PubMed Web of Science ®Google Scholar
• Li Z, Yu X, Shen J, Jiang Y. MicroRNA dysregulation in uveal melanoma: a new player enters the game. Oncotarget. 2015;6(7):4562–4568. doi:10.18632/oncotarget.2923
   Google Scholar
• Liu N, Sun Q, Chen J, et al. MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-kappaB1 pathway. Oncol Rep. 2012;28(3):961–968. doi:10.3892/or.2012.1905
   PubMed Web of Science ®Google Scholar
• Radhakrishnan A, Badhrinarayanan N, Biswas J, Krishnakumar S. Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma. Mol Vis. 2009;15:2146–2154.
   PubMed Web of Science ®Google Scholar
• Yang C, Wei W. The miRNA expression profile of the uveal melanoma. Sci China Life Sci. 2011;54(4):351–358. doi:10.1007/s11427-011-4149-y
   Web of Science ®Google Scholar
• Chen X, He D, Dong XD, et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54(3):2248–2256. doi:10.1167/iovs.12-10977
   PubMed Web of Science ®Google Scholar
• Rothwell DG, Smith N, Morris D, et al. Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol Oncol. 2016;10(4):566–574. doi:10.1016/j.molonc.2015.11.006
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599–602. doi:10.1038/nature07586
   PubMed Web of Science ®Google Scholar
• Sellam A, Desjardins L, Barnhill R, et al. Fine needle aspiration biopsy in uveal melanoma: technique, complications, and outcomes. Am J Ophthalmol. 2016;162:28–34 e21. doi:10.1016/j.ajo.2015.11.005
   Web of Science ®Google Scholar
• Chang MY, Rao NP, Burgess BL, Johnson L, McCannel TA. Heterogeneity of monosomy 3 in fine needle aspiration biopsy of choroidal melanoma. Mol Vis. 2013;19:1892–1900.
   Web of Science ®Google Scholar
• Wu M, Wang G, Hu W, Yao Y, Yu XF. Emerging roles and therapeutic value of exosomes in cancer metastasis. Mol Cancer. 2019;18(1):53. doi:10.1186/s12943-019-0964-8
   PubMed Web of Science ®Google Scholar
• Kharaziha P, Ceder S, Li Q, Panaretakis T. Tumor cell-derived exosomes: a message in a bottle. Biochim Biophys Acta. 2012;1826(1):103–111. doi:10.1016/j.bbcan.2012.03.006
   PubMed Web of Science ®Google Scholar
• Bennett CW, Berchem G, Kim YJ, El-Khoury V. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. Oncotarget. 2016;7(43):71013–71035. doi:10.18632/oncotarget.v7i43
   Google Scholar
• Salvianti F, Massi D, De Giorgi V, Gori A, Pazzagli M, Pinzani P. Evaluation of the liquid biopsy for the detection of brafv600e mutation in metastatic melanoma patients. Cancer Biomark. Epub 2019 Sep 3.
   Web of Science ®Google Scholar